11 September 2024

Forbion Leads $14m Series A in SOLASTA Bio to advance development and commercialisation of first-in-class sustainable crop protection solutions

Forbion Leads $14m Series A in SOLASTA Bio

Joy Faucher, Partner at Forbion for its BioEconomy Fund noted, “As traditional insect control agents struggle with resistance and impact to biodiversity, SOLASTA’s demonstrated cost-effective, sustainable and high-efficacy solution is poised to transform the crop protection market. We are excited to support SOLASTA in continuing the development and commercialisation of its first-in-class peptide products.”

“We have come a long way since setting out on this journey 3 years ago. We have developed our unique technology platform to address grower pain points, have expanded operations to the US and have brough together outstanding competencies in technology and agribusiness. The results of our field trials have been hugely encouraging, demonstrating high efficacy of biopeptides against target insect pests, as effective or better than standard insecticides” said Shireen Davies PhD, FRSE, CEO and co-founder, SOLASTA Bio. “With the Series A, it’s time for SOLASTA Bio to kick on to the next level and successfully hit our targets for commercialisation.”